Although many people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...
Medically reviewed by Leah Ansell, MDMedically reviewed by Leah Ansell, MD Plaque psoriasis is the most common type of psoriasis. Plaques are pink/red, raised, thick, inflamed skin patches covered by ...
Creams play an important role in the treatment of plaque psoriasis to help improve the appearance of the skin and reduce itching. New medicines that target the underlying inflammation caused by plaque ...
ORLANDO, Fla. — In moderate to severe plaque psoriasis, two highly selective oral TYK2 inhibitors produced a level of response in phase 2 studies suggesting that drugs in this class might rival ...
The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis of the scalp and body in adult and pediatric ...
84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 ...
A standardized definition of on-treatment remission in plaque psoriasis is crucial for aligning treatment goals and improving patient care. Remission is defined as maintaining 0% BSA involvement or an ...
Otezla is the first oral therapy approved for moderate to severe plaque psoriasis in this patient population. The Food and Drug Administration (FDA) has expanded the approval of Otezla ® (apremilast) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results